CoViD-19: Pharmaceutical care during early disease

Research output: Contribution to journalLetter

Abstract

Coronavirus may likely stay with us forever [1] and you have rightly mentioned in your recent editorial [2] that it is the time to shift the focus on living with the disease. An approved drug or vaccine to treat or prevent the disease is still far and may not be readily available across the world in the near future, particularly in the low and middle-income countries. Therefore, a comprehensive pharmaceutical care during early CoViD-19 is invaluable in supporting patients under self-isolation or in quarantine to help with their symptoms and preventing them from getting a severe disease needing hospitalisation. A recent preprint [3] provides a pharmaceutical care plan for the early CoViD-19 as an alternative approach to manage the pandemic in the absence of a ‘breakthrough’ drug or a fully established coronavirus vaccination program. The given approach aims to hit the coronavirus hard within the upper respiratory tract before it goes down to cause a severe disease.
Original languageEnglish
Article numberbmj.m2035/rr-2
Number of pages1
JournalThe BMJ
Publication statusPublished - 29 May 2020

Fingerprint Dive into the research topics of 'CoViD-19: Pharmaceutical care during early disease'. Together they form a unique fingerprint.

  • Cite this